Physician profile
Eric D King
NPI 1427101922
$8,897.16
in general payments reported to CMS, 2019-2025
31 companies · $2,504 in 2025
The $2,504 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,667 · 2022: $306 · 2023: $1,925 · 2024: $2,495 · 2025: $2,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,376 · Education: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,375.87 |
| Education | $548.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,872.51 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,046.09 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $857.51 | 2021-2025 | |
| Lilly USA, LLC | $752.80 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $592.48 | 2023-2024 | Sotyktu |
| Leo Pharma INC. | $573.85 | 2021-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $525.18 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $479.07 | 2024-2025 | Tremfya, Simponi Aria, Simponi |
| Galderma Laboratories, L.P. | $443.32 | 2021-2025 | Nemluvio, Dysport, Aklief |
| Incyte Corporation | $337.64 | 2021-2025 | Opzelura |
| Amgen INC. | $258.67 | 2021-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $182.81 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $151.00 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $135.39 | 2021-2025 | |
| Pfizer INC. | $102.78 | 2021-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $83.10 | 2021 | |
| Dermavant Sciences, INC. | $65.18 | 2023-2024 | Vtama |
| Boston Scientific Corporation | $63.42 | 2021 | |
| Botanix Sb INC | $52.24 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $51.05 | 2024 | Ycanth |
| Biofrontera INC. | $49.50 | 2021 | |
| Almirall LLC | $44.45 | 2021 | |
| Intuitive Surgical, INC. | $28.61 | 2024 | |
| Sanofi-Aventis U.S. LLC | $25.00 | 2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $22.63 | 2025 | |
| Allergan, INC. | $22.19 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.33 | 2024 | Spevigo |
| Vyne Pharmaceuticals INC. | $18.93 | 2021 | |
| Dermira, INC. | $18.23 | 2021 | |
| Mission Pharmacal Company | $13.53 | 2021 | |
| Organon LLC | $7.67 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.